Novartis AG
- Country
- π¨πSwitzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 250
- Registration Number
- NCT00171405
- Locations
- π¬π§
Investigative Site, London, United Kingdom
Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled With Amlodipine Alone
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 936
- Registration Number
- NCT00171002
- Locations
- π¨π
Novartis Pharmaceuticals, Basel, Switzerland
A Year Long Study to Evaluate the Safety of the Combination of Valsartan (320 mg) and Amlodipine (5 mg) in Patients With Hypertension
- Conditions
- HYPERTENSION
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Novartis
- Target Recruit Count
- 403
- Registration Number
- NCT00170976
- Locations
- π©πͺ
Sites in germany, Multiple Locations, Germany
π¨πNovartis Pharmaceuticals, Basel, Switzerland
Efficacy and Safety of Diclofenac Sodium Gel in Knee Osteoarthritis
- Conditions
- Osteoarthritis
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-04-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 480
- Registration Number
- NCT00171626
- Locations
- πΊπΈ
Novartis Consumer Health Inc, Parsippany, New Jersey, United States
Safety of Diclofenac Sodium Gel in Knee Osteoarthritis
- Conditions
- Osteoarthritis
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-04-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 450
- Registration Number
- NCT00171691
- Locations
- πΊπΈ
Novartis Consumer Health Inc., Parsippany, New Jersey, United States
Efficacy and Safety of Diclofenac Sodium Gel in Knee Osteoarthritis
- Conditions
- Osteearthritis
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-04-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 480
- Registration Number
- NCT00171678
- Locations
- πΊπΈ
Novartis Consumer Health Inc., Parsippany, New Jersey, United States
Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and Cognitive Impairment
- Conditions
- Traumatic Brain Injury
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 67
- Registration Number
- NCT00171795
Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction
- Conditions
- HypertensionDyslipidemia
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 213
- Registration Number
- NCT00171327
- Locations
- π·πΊ
Novartis, Moscow, Russian Federation
Valsartan/Hydrochlorothiazide Combination in Hypertensive Patients Not Controlled With Valsartan Alone
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 2714
- Registration Number
- NCT00170989
- Locations
- π¨π
Novartis Pharmaceuticals, Basel, Switzerland
To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.
- Conditions
- Diastolic DysfunctionHypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 317
- Registration Number
- NCT00170924
- Locations
- πΊπΈ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States